Naluzotan Hydrochloride

N/A

Report date: 2022/08/29 20:00:24
NME

Base Information

Drug NameNaluzotan Hydrochloride
Drug Alias Name纳鲁佐坦Naluzotan那鲁佐坦NaluzotanumPRX-00023
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerotonin 1a (5-HT1a) receptor agonists
TargetsSerotonin 1a (5-HT1a) receptor
Therapy Area/IndicationsDepressive Disorder, MajorAnxiety DisordersEpilepsy, Temporal Lobe +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesEpix
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesEpix Pharmaceuticals IncNational Institute Of Neurological Disorders And Stroke
Active IndicationsN/A
Inactive IndicationsDepressive Disorder, MajorAnxiety DisordersEpilepsy, Temporal Lobe +[5] 

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG